<--GAT-->
Clinical Topics

Parkinson’s Drug Not Associated With Higher Prostate Cancer Risk

by U.S. Medicine

September 9, 2018

SILVER SPRING, MD—An increased incidence of prostate cancer was observed in Parkinson’s disease (PD) patients treated with entacapone during a pre-approval randomized clinical trial, according to a new study which noted that the relationship had not yet been intensely investigated.

Entacapone is used with levodopa and carbidopa to prolong the effects in the brain.

In response, researchers from the U.S. Food and Drug Administration (FDA) sought to investigate whether entacapone is associated with prostate cancer and whether the drug is linked to advanced disease at the time of cancer diagnosis. Results were published in the journal Parkinsonism & Related Disorders.1

The FDA team used data from the VA’s healthcare system, focusing on Parkinson’s patients treated with add-on entacapone or add-on dopamine agonist/monoamine oxidase B inhibitors between January 2000 and December 2014. Veterans were followed on treatment for occurrence of prostate cancer, which was identified through linkage to the VA cancer registry.

Overall, 17,666 patients, mean age 74, met study criteria, with the entacapone-treated group including 5,257 subjects. Over mean follow-up time of 3.1 and 4.0 years in the entacapone and control cohort, respectively, 23 prostate cancer cases occurred in the entacapone cohort and 97 in the control cohort.

Results indicated that the overall incidence of prostate cancer was 1.8 per 1,000 person-years of risk. No difference in risk of prostate cancer was detected between the cohorts for increased duration of entacapone intake (adjusted HR: 1.08; 95% confidence interval: 0.46–2.51 for cumulative exposure of two or more years). Furthermore, researchers noted, Time since starting drug therapy and cumulative dose (mg) also did not point to a difference in prostate cancer risk between cohorts.

“Prolonged therapy with entacapone was not associated with increased prostate cancer incidence; however, findings suggest a higher severity of prostate cancer,” study authors concluded.

1. Major JM, Dong D, Cunningham F, By K, Hur K, Shih DC, Jiang R, Podskalny GD, Wei X, Pinheiro S, Bird ST, Keeton S, Graham DJ. Entacapone and prostate cancer in Parkinson’s disease patients: A large Veterans Affairs healthcare system study. Parkinsonism Relat Disord. 2018 May 5. pii: S1353-8020(18)30220-7. doi: 10.1016/j.parkreldis.2018.04.035. [Epub ahead of print] PubMed PMID: 29759929.


Related Articles

“Coming together is a beginning. Keeping together is progress. Working together is success.” — Henry Ford (1863-1947)

October is Operation Bushmaster season for Uniformed Services University (USU) medical and nursing students.

NASA Partners with Academia for CVD Prediction Tool in Younger Adults

Federal medicine played a crucial role in the development of a new online tool to better predict which middle-aged adults are at the greatest risk of having acute myocardial infarction or stroke over the next decade.


U.S. Medicine Recommends


More From oncology

Oncology

VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

Oncology

VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.

Oncology

Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.

Oncology

Side-effects Differ Between Radiation Therapies for Prostate Cancer

A recent study compared patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.

Oncology

Metformin Promising for Improving Prostate Cancer Survival

Metformin, a commonly used drug for patients with Type 2 diabetes mellitus (DM), has shown promise in helping to treat prostate cancer (PCa), according to a new study.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up